Module 29 · Toxicology & envenomation

Snakebite, scorpion and envenomation

NewPhase 1

Snakebite and envenomation for Indian ICUs: recognising neurotoxic and haemotoxic syndromes, the 20-minute whole blood clotting test, ASV dosing and reactions under the national protocol, ventilation and the neostigmine trial for neuroparalysis, scorpion sting with prazosin, and bee and wasp stings.

6 topics

Drugs in this module

Doses written for this module's context. The same drug may read differently in another module.

Anti-snake venom (polyvalent ASV)

Equine F(ab')2 polyvalent antivenom (Big Four)

Indications
Systemic envenoming (incoagulable 20WBCT, spontaneous bleeding, neuroparalysis, shock, AKI, rhabdomyolysis) or rapidly progressive local swelling (> half the limb, or within hours).
Adult dose
10 vials IV (reconstituted, in ~200 mL NS) over 1 h; same dose for children and pregnant women. Haemotoxic: repeat 10 vials if 20WBCT still incoagulable at 6 h (usual max 25-30 vials). Neurotoxic: repeat 10 vials if no improvement at 1-2 h (usual max 20 vials).
Preparation (India)
Lyophilised vials (each neutralises a stated mg of each venom per 10 mL); reconstitute with 10 mL water for injection. Several Indian manufacturers (e.g. Bharat Serums, VINS, Premium Serums).
Cautions
No test dose (poor predictive value, delays treatment). Early anaphylactoid reactions in up to ~20-40%: keep adrenaline drawn up. Pyrogenic reactions; serum sickness at 5-24 days.

Adrenaline (epinephrine)

Sympathomimetic

Indications
ASV reactions, anaphylaxis to Hymenoptera stings; shock.
Adult dose
0.5 mg IM (0.5 mL of 1 mg/mL) into anterolateral thigh, repeat every 5-15 min; child 0.01 mg/kg IM (max 0.5 mg). Refractory: IV infusion 0.05-0.5 mcg/kg/min.
Preparation (India)
1 mg/mL (1:1000) 1 mL ampoules.
Cautions
Never give 1 mg/mL IV as a bolus. Tachyarrhythmia, hypertension.

Neostigmine

Anticholinesterase

Indications
Neostigmine trial in neurotoxic (especially cobra, postsynaptic) envenoming with ptosis or weakness.
Adult dose
After atropine 0.6 mg IV: neostigmine 1.5 mg IV (or 0.5 mg IM); if improvement, continue 0.5 mg IV every 30 min (up to 5 doses), then taper. Child: atropine 0.05 mg/kg + neostigmine 0.04 mg/kg.
Preparation (India)
0.5 mg/mL 1 mL ampoules (Myostigmin).
Cautions
Always pre-treat with atropine (bradycardia, bronchorrhoea). Little benefit in krait (presynaptic) bites.

Atropine

Antimuscarinic

Indications
Premedication before neostigmine; bradycardia and cholinergic features in scorpion sting only if severe (generally avoided).
Adult dose
0.6 mg IV before each neostigmine dose (child 0.05 mg/kg).
Preparation (India)
0.6 mg/mL 1 mL ampoules.
Cautions
Avoid routine use in scorpion sting – worsens the adrenergic storm.

Prazosin

Alpha-1 adrenergic blocker

Indications
Indian red scorpion (Mesobuthus tamulus) sting with autonomic storm: hypertension, tachycardia, cold extremities, pulmonary oedema risk.
Adult dose
30 mcg/kg orally (adult typically 0.5-1 mg) every 3 h until peripheries warm and features resolve; via nasogastric tube if needed.
Preparation (India)
1 mg, 2 mg, 5 mg tablets (Minipress XL is extended-release – use immediate-release where possible).
Cautions
First-dose postural hypotension – keep supine; correct volume. Extended-release preparations act too slowly.

Module references (5)

  1. 1

    Directorate General of Health Services, Ministry of Health and Family Welfare, Government of India. Standard Treatment Guidelines: Snakebite. New Delhi: MoHFW/NHSRC; June 2016

  2. 2

    World Health Organization Regional Office for South-East Asia. Guidelines for the management of snakebites. 2nd ed. New Delhi: WHO SEARO; 2016

  3. 3

    Lamb T, Abouyannis M, de Oliveira SS, et al. The 20-minute whole blood clotting test (20WBCT) for snakebite coagulopathy – a systematic review and meta-analysis of diagnostic test accuracy. PLoS Negl Trop Dis. 2021;15(8):e0009657

  4. 4

    Bawaskar HS, Bawaskar PH. Efficacy and safety of scorpion antivenom plus prazosin compared with prazosin alone for venomous scorpion (Mesobuthus tamulus) sting: randomised open label clinical trial. BMJ. 2011;342:c7136

  5. 5

    Cardona V, Ansotegui IJ, Ebisawa M, et al. World Allergy Organization anaphylaxis guidance 2020. World Allergy Organ J. 2020;13(10):100472